Deal, C,
Steelman, J,
Vlachopapadopoulou, E,
Stawerska, R,
Silverman, LA;,
Phillip, M,
Kim, HS,
Ko, CW,
Malievskiy, O,
Cara, JF,
Roland, CL,
Taylor, CT,
Valluri, SR,
Wajnrajch, MP,
Pastrak, A,
Miller, BS (2022) for
once-weekly treatment of children with
growth hormone deficiency (GHD).
Objective: We aimed to compare
Maniatis, AK;,
Casella, SJ;,
Nadgir, UM;,
Hofman, PL;,
Saenger, P;,
Chertock, ED;,
Aghajanova, EM;,
Korpal-Szczyrska, M;,
Vlachopapadopoulou, E;,
Malievskiy, O;,
Chaychenko, T;,
Cappa, M;,
Song, WJ;,
Mao, M;,
Mygind, PH;,
Smith, AR;,
Chessler, S;,
Komirenko, AS;,
Beckert, M;,
Aimee, D Shu,
Paul, S Thornton (2022) -tolerated, with no new safety signals identified. Children treated with
once-weekly lonapegsomatropin showed continued
Musin, I. I.,
Yashchuk, A.G.,
Pavlov, V.N.,
Wang, J.,
Sun, X.,
Naftulovich, R.A.,
Popova, E.M. (2022) using Miyazaki's technique. Conclusions: Considering the Food and Drug
Administration's 2019 decision
Mukhametov, U.F.,
Lyulin, S.V.,
Borzunov, D.Y.,
Gareev, I.F.,
Beylerli, O.A.,
Sufianov, A.A. (2022) confirm that ectopic bone formation is one of the side effects following
administration of rh
ПУЛЬСАЦИОННЫЙ ИНДЕКС МАТОЧНЫХ АРТЕРИЙ В СРОКЕ ГЕСТАЦИИ 11-14 НЕДЕЛЬ КАК ПРЕДИКТОР ПРЕЭКЛАМПСИИPULSATING INDEX OF UTERINE ARTERIES IN 11-14
WEEKS OF GESTATION AS A PREDICTOR OF PREECLAMPSIA